Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.13 | N/A | -32.16% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.13 | N/A | -32.16% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern about the company's current position and highlighted the importance of adapting to market conditions.
Management acknowledged the challenges faced during the quarter.
They emphasized the need for strategic adjustments moving forward.
The earnings report indicates that Kodiak Sciences is struggling, particularly with its EPS performance, which fell short of expectations. The significant drop in stock price, down 29.4%, reflects investor disappointment and concerns about the company's future direction. Without any guidance provided, uncertainty remains about how Kodiak plans to navigate these challenges ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GAMESTOP CORP NEW A
Mar 26, 2024